NCT03618381View on ClinicalTrials.gov

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 18, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2040

Conditions
Pediatric Solid TumorGerm Cell TumorRetinoblastomaHepatoblastomaWilms TumorRhabdoid TumorCarcinomaOsteosarcomaEwing SarcomaRhabdomyosarcomaSynovial SarcomaClear Cell SarcomaMalignant Peripheral Nerve Sheath TumorsDesmoplastic Small Round Cell TumorSoft Tissue SarcomaNeuroblastoma
Interventions
BIOLOGICAL

second generation 4-1BBζ EGFR806-EGFRt

Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt

BIOLOGICAL

second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG

Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG

Trial Locations (1)

98105

RECRUITING

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER